PDS Planning Inc Has $397,000 Position in Cencora, Inc. $COR

PDS Planning Inc raised its stake in Cencora, Inc. (NYSE:COR) by 10.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,325 shares of the company’s stock after purchasing an additional 127 shares during the period. PDS Planning Inc’s holdings in Cencora were worth $397,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of COR. Cornerstone Planning Group LLC grew its stake in shares of Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company’s stock valued at $26,000 after acquiring an additional 48 shares in the last quarter. Hoey Investments Inc. acquired a new position in shares of Cencora in the first quarter valued at about $28,000. Costello Asset Management INC acquired a new position in shares of Cencora in the first quarter valued at about $28,000. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Cencora in the first quarter valued at about $39,000. Finally, Golden State Wealth Management LLC grew its stake in shares of Cencora by 157.6% in the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company’s stock valued at $47,000 after acquiring an additional 104 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on COR shares. Jefferies Financial Group upped their price target on shares of Cencora from $275.00 to $300.00 and gave the company a “hold” rating in a research note on Monday, June 30th. Wall Street Zen downgraded shares of Cencora from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings restated a “buy (b)” rating on shares of Cencora in a research note on Wednesday. Evercore ISI set a $340.00 price objective on shares of Cencora in a research report on Wednesday. Finally, Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $320.00.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the completion of the transaction, the chief executive officer owned 39,274 shares of the company’s stock, valued at approximately $11,389,460. This represents a 11.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold 55,993 shares of company stock valued at $16,292,923 in the last three months. Company insiders own 10.80% of the company’s stock.

Cencora Trading Up 1.2%

COR opened at $318.01 on Friday. Cencora, Inc. has a twelve month low of $221.95 and a twelve month high of $319.68. The company has a 50-day simple moving average of $296.99 and a 200 day simple moving average of $291.75. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The stock has a market capitalization of $61.66 billion, a price-to-earnings ratio of 32.72, a P/E/G ratio of 1.49 and a beta of 0.63.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, topping analysts’ consensus estimates of $3.79 by $0.21. The firm had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.34 earnings per share. Analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is 22.63%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.